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Abstract In the last decade, PET-only systems have been
phased out and replaced with PET-CT systems. This merger
of a functional and anatomical imaging modality turned out
to be extremely useful in clinical practice. Currently, PET-
CT is a major diagnostic tool in oncology. At the dawn of
the merger of MRI and PET, another breakthrough in
clinical imaging is expected. The combination of these
imaging modalities is challenging, but has particular
features such as imaging biological processes at the same
time in specific body locations.
Keywords CT—Computed tomography.PET—Positron
Emission Tomography.MRI—Magnetic Resonance
Imaging.MRS—Magnetic Resonance Spectroscopy.
Staging of Cancer.Therapy Monitoring.
FDG—
18F Fluoro-deoxy-glucose
Introduction
In oncology, detection of tumor, staging of disease, and
monitoring of therapy are important for patient manage-
ment and prognosis [1]. Cancer patients undergo a number
of different imaging studies throughout the course of their
disease. Various imaging investigations are available and
the resulting images are reviewed on different viewing
stations. The gathered information is synthesized and
integrated by the interpreting physician(s). The multitude
of images need to be correlated, and can be co-registered or
aligned retrospectively and fused in computer memory. Post
hoc image fusion, based on tomograms acquired at different
institutions, on separate days, using varying equipment and
protocols, is a tedious and time-consuming task. Moreover,
well-defined and reproducible landmarks are necessary to
provide the coordinate system in which the images can be
aligned, scaled and registered. Since patient positioning
varies widely between PET and CT, e.g. arms up or down,
different patient and organ axes, the post hoc fusion technique
is prone to mis-alignment, inconsistencies and errors. Also,
there may be problems due to patient movement as well as
motion of internal organs. Changes related to breathing and
organ movement such as a beating heart, are inevitable, and
cannot be controlled when a patient is imaged on different
machines and at different times, even when care is taken to
ensure that the body position of the patient is the same (e.g.
with external lasers in 3D). Other movements such as bowel
peristalsismaybeminimizedwithmedication.Brownadipose
tissue uptake may be aborted with sympathetic nervous
system receptor blocking agents.
In the last decade, this journal has reported on the
developments of imaging in oncology, from the progress of
PET-only [2] to combining PET and CT [3] and PET and
MRI [4]. Reviews have been published on some of the
achievements of the dual imaging modality PET/CT, a
powerful, routinely and frequently applied molecular
imaging tool for diagnosis, staging and therapy monitoring
in oncology [5–8].
PET-CT imaging
For an oncology study the most often used radiopharmaceu-
tical is
18F-FDG [9]. FDG mimics the glucose utilization,
C. Schiepers (*): M. Dahlbom
Molecular & Medical Pharmacology,
David Geffen School of Medicine at UCLA,
University of California,
200 Medical Plaza, Suite B-114,
Los Angeles, CA 90095-7370, USA
e-mail: cschiepers@mednet.ucla.edu
Eur Radiol (2011) 21:548–554
DOI 10.1007/s00330-010-2033-ywhich is usually deranged in cancer. Typically, 200–
600 MBq of
18F-FDG is administered to the patient,
followed by a 1 h uptake interval. During this uptake
interval, oral contrast medium may be administered, e.g. at 5,
30, and 55 min relative to the FDG injection, for improved
detection of abdominal and pelvic abnormalities by CT.
After voiding, the patient is positioned in the PET/CT
system. The photon emissions from the
18F label do not
interfere with the CT detectors, which have lower sensitivity
for the high-energy photons from the annihilation. In
addition, the photon flux from
18F-FDG is a power of 4
lower than from the X-ray tube.
A scout view is obtained and the imaging field defined.
Subsequently, a helical CT dataset is acquired without and/
or with intravenous contrast medium. The complete CT
data acquisition takes 0.5–1.5 min, depending on the axial
field of view and type of CT system incorporated into the
PET/CT machine. The patient bed is then translated axially
into the PET field-of-view and PET data [10] acquired over
the same axial range as the CT. The duration of the PET
data acquisition is 5–25 min dependent on the axial field-
of-view, the type of detectors and mode of acquisition (2D
vs 3D). The CT data are used for attenuation correction,
omitting the lengthy transmission with radioactive sources
which was used previously [3]. If an enhanced CT study is
requested or deemed appropriate, the additional CT
acquisition is performed after the standard PET-CT study
is completed, to ensure correct attenuation correction [3].
Intravenous contrast medium (usually about 300 mg/ml
iodine) at a rate of 1–2 ml/sec is administered up to 125 ml.
Current multidetector CT systems are sufficiently fast to
permitmulti-phase imaging.An enhancedCTfollowing PET/
CT is generally limited to a specific area of the body, e.g.
chest,liver orpelvis,inorder toreducethe total radiationdose
to the patient. If a dedicated head & neck CT examination is
required, the intravenous dose of contrast agent can be split in
two, 80 ml for the body followed by 45 ml for the H&N.
The absorbed radiation dose from some whole body CT
examinations is significant (7–14 mSv), and an additional
dedicated CT increases the absorbed radiation dose.
The combined CT-PET-CT acquisition generally takes
less than half an hour.
The contribution of breathing is less important for the
abdomen than for the chest [11]. The artifact caused by
motion of the liver during CT acquisition, does not pose a
real clinical problem in staging primary hepatic cancer or
extent of liver metastases [12]. Non-attenuation corrected
tomograms and projection images are always available to
check for possible artifacts induced by mis-registered PET-
CT slices. Metal implants or contrast material may also
induce artifacts. Therefore, non-attenuation corrected
images are routinely interpreted to check for and eliminate
possible imaging artifacts. Modern reconstruction algo-
rithms are less sensitive to metal artifacts, dental implants,
oral and intravenous contrast agents [13, 14].
During the last decade, PET-only systems have disap-
peared from the clinical armamentarium, and have largely
been replaced with PET-CT equipment. From a patient point
of view, it is convenient only to have to make a single visit to
the imaging suite for diagnostic work-up. Several reviews on
the achievements are available in the literature [15–18].
In 2003, Blomqvist and Torkzad wrote in JAMA [19]
that: ‘the dual-imaging modality PET/CT is relatively new’,
and is used mostly: ‘in patientswith lung cancer’.A so f2 0 1 0 ,
the application of this type of dual modality diagnostic
imaging is the standard in oncology and the current state-of-
the-art in staging of disease and monitoring of treatment.
Many studies have been reported and reviews published
for common and less common cancers [16, 20–23]; others
were focused on lung [17, 24] , breast [25–29], colorectal
[30–32], recurrent rectal [33], head & neck [34–36],
ovarian [22], uterine [37] and cervical [38, 39], nasopha-
ryngeal [40] and thyroid cancer [41, 42], melanoma [43–
45], as well as lympho-proliferative disorders [46–48],
carcinoma of unknown primary (CUP) [49], and primary
muscular-skeletal tumors [8].
Several publications deal with false positive results [50],
artifacts and pitfalls [51], and with problems about SUV
[52, 53], the standardized uptake value, a parameter that is
used for semi-quantitative purposes, especially for longitu-
dinal and serial comparisons [54]. Bowel preparation was
reported by Blake et al. [55].
The role of FDG in therapy monitoring was reviewed in
2005 [6] and 2009 [56].
The contribution of PET/CT in radiation therapy
planning has been established for the common cancers
[57–59], and head & neck [60].
The latest addition to clinical PET/CT imaging is Time-
of-Flight (TOF), where the time differences between the
detection of the annihilation photons is taken into account.
Using this information in the image reconstruction, it can
be shown that a gain in image signal-to-noise ratio can be
achieved, in particular for large objects [61]. This technique
is not new, was introduced a few decades ago [62] but
lacked the proper detection material and electronics to
produce the anticipated improvement in image quality.
Using TOF indirectly improves the spatial resolution since
less spatial filtering is necessary to maintain the image
signal-to-noise (S/N) ratio. However, TOF requires fast
scintillation detectors and additional fast and optimized
electronics, which increases the cost. The intrinsic FWHM
of a modern PET/CT scanner such as the Siemens® mCT®
(Forchheim, Germany) with TOF and ultra-HD PET,
improves the spatial resolution from 4 to 2 mm.
In Fig. 1, images are shown of a diagnostic study with
conventional PET/CT and TOF-PET/CT.
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Combining anatomical MR imaging with the molecular
PET, potentially offers the advantages that are seen in PET/
CT. In addition, the advent of MR spectroscopy (MRS),
another molecular imaging technique, might be fused as
well [3].
Post hoc or software based image fusion of MR and PET
images has the same disadvantages as PET/CT. For PET/
CT, the solution turned out to be ‘mechanical’ or ‘in-line’
Fig. 1 Maximum projection image in the anterior view for TOF-PET
(a) and PET (b) of a woman with breast cancer. Note the difference in
contrast and intensity of the lesions in the left breast and axilla.
Coronal slices for CT (left panel) and PET (right panel), and the fused
PET-CT (middle) are given for TOF-PET (c) and PET (d). The
difference in contrast can still be appreciated. TOF contributes most in
obese patients, who have higher scatter of the emitted photons.
Preservation of the S/N ratio and improved spatial resolution of TOF
enhances lesion contrast. Patient weight was 120.2 kg; administered
activity 606 MBq of
18F-FDG; total acquisition time of PET/CT was
21 min
550 Eur Radiol (2011) 21:548–554fusion. This means that the acquisitions of CT and PET are
separated in space and in time, and are not simultaneous.
The bed for image acquisition, however, is the same for CT
and PET; the patient is in the same position on this bed,
whereas fusion happens later in computer memory. The
main reason for non-simultaneous acquisition is the lack of
detectors with ‘reasonable’ efficiency for both the 60–
120 keV photons from CT and the 511 keV annihilation
photons from PET [3]. Since the detectors for MR and PET
imaging are totally different, another type of gantry is
necessary to combine these two modalities. MR imaging
takes much longer than multi-detector CT and the acquisi-
tion times for MR and PET become similar. Thus, the
‘simultaneous’ acquisition option for MR and PET appears
extremely appealing (Fig. 2). The ‘sequential’ option (used
in PET/CT) would lead to much longer acquisition times
for MR/PET, i.e. time that the patient has to be inside the
scanners (Fig. 3). In other words, patient movement and
motion artifacts are able to cause mis-registration and
disrupt the final image fusion quality.
A paramount advantage of the simultaneous acquisition
option is that we are interrogating and measuring the tissues
of the patient at exactly the same time. Thus, image
registration becomes trivial [63].
MR has no ionizing radiation, so the combined MR/PET
and MRS absorbed radiation dose to the patient is solely
due to the administered radiopharmaceutical. This is much
more favorable than CT, which has a relatively high
radiation burden, especially with the current deep inspira-
tion, multi-phase with and without contrast medium, and
shallow breathing protocols.
There are a number of challenges in combining PET and
MRI. The PMTs (photo-multiplier tubes) used in conven-
tional PET detectors are highly sensitive to magnetic fields
and cannot be used near the MR magnet. Solid-state
detectors are less sensitive to magnetic fields and have
been shown to operate relatively undisturbed in strong
magnetic fields. These detectors have to be constructed
without any ferromagnetic materials that would otherwise
produce heterogeneity within the magnetic field. These
challenges have therefore resulted in different approaches
for combined MR/PET systems [64].
Simultaneous acquisition
In order to simultaneously perform PET and MR
imaging, the PET detectors have to be able to operate
inside the magnetic field without interfering with the MR
imaging. These types of detectors have successfully been
constructed and are typically based on silicon avalanche
photo-detectors (APDs) [64]. Several animal systems
based on this technology have been constructed and
Siemens® introduced a PET insert for one of their MR
systems in 2007. This system has a relatively long axial
FOV 19.25 cm, but because of the small detector diameter
of 35.5 cm it is limited to brain imaging [65]. A recent
clinical study comparing PET/CT and MR/PET imaging
showed that the image quality was similar for both
systems [66]. MR/PET offers additional advantages such
as higher tissue contrast, sophisticated MR imaging
techniques such as perfusion and diffusion imaging [67],
and MR spectroscopy, without adding extra radiation to
the patient. It is very likely that this technology will be
extended to clinical whole body imaging in the very near
future [4].
Sequential acquisition
In the Philips’® (Eindhoven, Netherlands) MR/PET
system, a different system design is used. The conven-
tional PET and MRI gantries are placed at some distance
from each other in order to minimize interference
between the two systems. The two devices use a
common patient bed, which can be moved into either
imaging gantry. This solution does not require special
PET detectors, although additional magnetic shielding is
placed around the PET gantry to minimize the effect on
the PMTs. This solution has the drawback of not
allowing simultaneous PET and MR imaging, which
prevents imaging of physiological and biochemical
processes at the same moment in time by the two
modalities. Since the PET and MRI data sets are acquired
sequentially and since MR imaging usually takes much
longer than CT, the imaging sessions are substantially
longer compared to corresponding PET/CT imaging
procedures.
Fig. 2 Simultaneous acquisition of MR and PET data. The RF (radio-
frequency) coil is located inside the ring of PET detectors
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Current limitations of MR are the thick slices (5–7m mi nz -
plane), whereas PET is already at 2–4 mm, especially with
the TOF electronics.
Another challenge for a combined MR/PET system is the
attenuation correction [68]. Since a set of CT images
represent a map of attenuation coefficients, these images
can relatively easily be converted to attenuation maps at
511 keV using a scaling technique.
However, the pixel values in an MR image represent
completely different physical properties (i.e., proton densi-
ty, relaxation times, etc), and the conversion of these pixel
values to attenuation coefficients at 511 keV is far from
straightforward. Since the attenuation coefficients in soft
tissue are relatively uniform at 511 keV, most visualized
tissue types can be assigned a population average.
However, tissues of significantly lower density such as
lung may require built-in intelligence in the processing
software to assign the correct attenuation values. An
additional complication is that not all tissue types are
visualized in MRI (e.g. bone). This may require the use of
deformable anatomical atlases to generate the correct
attenuation coefficients.
Further complications in using the MR images for
attenuation correction is that many of the objects used to
form the MR images (e.g., coils) are not visualized in the
MR images, but will attenuate the 511 keV photons.
Attenuation by these objects will therefore have to be
measured, and their locations during the MR/PET data
acquisition have to be determined. The conversion of MR
images to attenuation maps is a complex problem and is an
area of active research. A number of different approaches
are currently being investigated and developed [4, 65].
Summary
Our experience shows that the field of combined and
correlative imaging is changing, and the radiologist or
nuclear medicine specialist must be eager to participate in
this evolving field of molecular imaging. For oncological
applications, the importance of having a detailed anatom-
ical framework that permits accurate interpretation of
functional images cannot be over-emphasized. The require-
ments for such a reference framework will become
increasingly important with the development of more
specific tracers such as amino-acids, precursor, transporter,
receptor and gene-imagers [69].
Here, we alluded to the acceptance of PET/CT imaging
as the standard in diagnostic imaging for oncology. Patient
preparation is similar for a PET/CT compared to a routine
CT or PET study. For patients, the dual imaging session is
beneficial by saving time. For imaging specialists, the
combined equipment enhances patient throughput, and
technological innovations lead to superior image quality.
Image fusion has improved lesion localization, and
increased accuracy in staging of disease.
It is expected that MR/PET will follow a similar stellar
development. The simultaneous acquisition of data in this
dual imaging setting will undoubtedly benefit image
registration and reduce artifacts, and thus improve accuracy.
Correction for photon attenuation of the PET images is not
as straightforward as it was with PET/CT but several
Fig. 3 Sequential acquisition, i.e. both in space and in time, of MR and PET data. The two gantries are standard and in different locations.
Additional shielding against the magnetic field is necessary for the PET electronics
552 Eur Radiol (2011) 21:548–554solutions are possible. The combination with techniques
such as diffusion and perfusion imaging, as well as
molecular imaging with MR spectroscopy will advance
the multimodality-imaging field to even higher levels and
broader applications.
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